← Back to headlines
Tarsus Acquires iRenix Medical for $75 Million
Tarsus has completed the acquisition of iRenix Medical for $75 million, thereby gaining control of the late-stage eye care asset IRX-101.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
